Mesa Laboratories Executes Previously-Announced Strategic Financing Plan

Core Insights - Mesa Laboratories, Inc. has successfully executed its financial strategy by repaying $97.5 million of its 1.375% Convertible Senior Notes due August 2025, utilizing funds drawn from its Credit Agreement [1][2] - The company aims to optimize its capital structure and reduce shareholder dilution while supporting long-term growth [2][5] Financial Performance - The company drew $97.0 million under its Amended and Restated Credit Agreement, increasing the total outstanding balance to $108 million [1] - Interest rate on the Credit Facility is currently 7.18% and is expected to decrease with future Federal Funds Rate reductions, with anticipated interest payments of approximately $2.7 million for Q2 FY 2026 [2][3] Debt Management - Mesa's total net leverage ratio was 3.16 as of June 30, 2025, defined as total debt minus unrestricted cash in excess of $10 million compared to trailing 12 months EBITDA [3] - The company made over $7 million in principal payments in Q1 FY 2026 and expects to make approximately $20 million in principal payments for the remaining quarters of FY 2026 [4] Company Overview - Mesa Laboratories, Inc. is a global leader in designing and manufacturing life science tools and quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries [6]